Tryptophan

Tryptophan

SCHEMBL537140

C[C@@H](O)[C@H](N)C(=O)O.N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.80
MAPT P10636 3/20 0.80
KMT2A Q03164 3/20 0.80
LMNA P02545 2/20 0.80
TSHR P16473 2/20 0.80
BLM P54132 2/20 0.80
PMP22 Q01453 2/20 0.80
MEN1 O00255 2/20 0.80
MPO P05164 1/20 0.80
HIF1A Q16665 1/20 0.80
APAF1 O14727 1/20 0.64
POLB P06746 1/20 0.64
RECQL P46063 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.61
HTR2A P28223 3/20 0.58
HTR1A P08908 2/20 0.58
HTR2C P28335 2/20 0.58
SLC6A4 P31645 2/20 0.58
HTR7 P34969 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tryptophan SCHEMBL6268677 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL27147785 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL12497478 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL537138 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL12497474 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL11217425 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL5481922 1.00 KDM4E (0.80) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL28120361 0.98 KDM4E (0.76) KDM4EMAPTKMT2ALMNATSHR
Tryptophan SCHEMBL7154073 0.96 KDM4E (0.74) KDM4EMAPTKMT2ALMNATSHR
Dl-Tryptophan SCHEMBL7859113 0.96 KDM4E (0.74) KDM4EMAPTKMT2ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383840-B1 Extraction of fulvic minerals, vitamins, amino acids, enzymes, and phytonutrients from humic substances MCMAHON GEOFF (US) 2013-02-26 US claimed
CN-117715632-A Compositions comprising an enzyme-cleavable prodrug and nafamostat and methods of use thereof 恩赛斯生物科学股份有限公司 2024-03-15 CN disclosed
CN-117279506-A Tumor storage and cell culture compositions 艾欧凡斯生物治疗公司 2023-12-22 CN disclosed
WO-2020081525-A1 ELECTROMAGNETIC AND FREQUENCY ENHANCED AGRICULTURE SONIPHI LLC (US) 2020-04-23 WO disclosed
CN-109689085-A COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION 阿塞勒隆制药公司 2019-04-26 CN disclosed
CN-107847561-A TGF- β superfamily type I and type II receptor heteromultimers and uses thereof 阿塞勒隆制药公司 2018-03-27 CN disclosed
CN-104662154-B Use the manufacture method of the lipid of thioesterase variant 花王株式会社 2017-09-01 CN disclosed
US-20170042209-A1 COMPOSITION COMPRISING SACHA INCHI PROTEIN IN COMBINATION WITH OTHER PLANT PROTEINS SHAKLEE CORPORATION 2017-02-16 US disclosed
WO-2017027599-A1 COMPOSITION COMPRISING SACHA INCHI PROTEIN IN COMBINATION WITH OTHER PLANT PROTEINS SHAKLEE CORPORATION (US) 2017-02-16 WO disclosed
US-20150301067-A1 METHODS AND ASSAYS FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2015-10-22 US disclosed
US-20070118916-A1 Process for the production of fine chemicals METANOMICS GMBH (DE) 2007-05-24 US disclosed
US-7211415-B2 Enterobacteriaceae strains over-expressing the yfiD gene for the fermentative production of L-amino acids DEGUSSA AG (DE) 2007-05-01 US disclosed
US-20040235122-A1 Process for the production of L-amino acids using strains of the enterobacteriaceae family EVONIK OPERATIONS GMBH (DE) 2004-11-25 US disclosed
EP-0975798-A1 METHOD TO DIAGNOSE AND TREAT PATHOLOGICAL CONDITIONS RESULTING FROM DEFICIENT ION TRANSPORT SUCH AS PSEUDOHYPOALDOSTERONISM TYPE-1 YALE UNIVERSITY (US) 2000-02-02 EP disclosed
EP-0946729-A2 PROTEINS WITH ENHANCED LEVELS OF ESSENTIAL AMINO ACIDS PIONEER HI-BRED INTERNATIONAL, INC. (US) 1999-10-06 EP disclosed
US-5888768-A CULTURE PRODUCT; GENETIC ENGINEERING ZYMOGENETICS, INC. (US) 1999-03-30 US disclosed
WO-1998040516-A1 METHOD TO DIAGNOSE AND TREAT PATHOLOGICAL CONDITIONS RESULTING FROM DEFICIENT ION TRANSPORT SUCH AS PSEUDOHYPOALDOSTERONISM TYPE-1 YALE UNIVERSITY (US) 1998-09-17 WO disclosed
WO-1998020133-A2 PROTEINS WITH ENHANCED LEVELS OF ESSENTIAL AMINO ACIDS PIONEER HI-BRED INTERNATIONAL, INC. (US) 1998-05-14 WO disclosed
EP-0015668-B1 DIGESTIBLE POLYAMINO ACIDS, METHOD FOR PREPARING THEM AND FOOD FORTIFIED WITH THE DIGESTIBLE POLYAMINO ACIDS Standard Oil Company (US) 1983-03-02 EP disclosed
US-4211795-A Animal feeds Institut National de la Recherche Agronomique and Aussedat-Rey (FR) 1980-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070118916-A1 Process for the production of fine chemicals POLRMT, POLI, POLM KDM4E 3359/4885MAPT 448/4885KMT2A 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.